Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 118.7% in the 3rd quarter, Holdings Channel reports. The fund owned 95,629 shares of the biopharmaceutical company’s stock after buying an additional 51,903 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Regeneron Pharmaceuticals were worth $38,638,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wrapmanager Inc. boosted its position in shares of Regeneron Pharmaceuticals by 9.9% during the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 130 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock worth $1,085,000 after buying an additional 141 shares during the period. Traynor Capital Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 9.8% during the second quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock worth $572,000 after buying an additional 145 shares during the period. Atria Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 10.9% during the second quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 147 shares during the period. Finally, MUFG Securities EMEA plc boosted its position in shares of Regeneron Pharmaceuticals by 1.7% during the second quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock worth $3,116,000 after buying an additional 152 shares during the period. Institutional investors and hedge funds own 66.06% of the company’s stock.
Several research firms have recently commented on REGN. TheStreet upgraded Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, July 25th. JPMorgan Chase & Co. set a $405.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday. Robert W. Baird lowered Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Friday, August 3rd. Cowen reiterated a “hold” rating and issued a $385.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $410.95.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.94 by $0.93. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the business earned $3.99 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals Inc will post 19.31 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the sale, the director now directly owns 13,000 shares of the company’s stock, valued at approximately $5,052,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The disclosure for this sale can be found here. Insiders have sold a total of 110,052 shares of company stock valued at $44,651,762 over the last ninety days. 12.42% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.wkrb13.com/2018/11/09/regeneron-pharmaceuticals-inc-regn-holdings-raised-by-skandinaviska-enskilda-banken-ab-publ.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: Market Capitalization
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.